Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.71 USD | +0.27% | +5.61% | -9.90% |
Sales 2024 * | 376M 30.09B | Sales 2025 * | 685M 54.78B | Capitalization | 3.41B 272B |
---|---|---|---|---|---|
Net income 2024 * | -183M -14.63B | Net income 2025 * | 53M 4.24B | EV / Sales 2024 * | 8.82 x |
Net cash position 2024 * | 84.87M 6.78B | Net cash position 2025 * | 153M 12.2B | EV / Sales 2025 * | 4.75 x |
P/E ratio 2024 * |
-18.7
x | P/E ratio 2025 * |
72.8
x | Employees | 545 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.69% |
Latest transcript on Axsome Therapeutics, Inc.
1 day | +0.27% | ||
1 week | +5.61% | ||
Current month | -10.14% | ||
1 month | -10.14% | ||
3 months | -20.18% | ||
6 months | +15.51% | ||
Current year | -9.90% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 11/01/12 | |
Nick Pizzie
DFI | Director of Finance/CFO | 49 | 15/05/18 |
Mark Jacobson
COO | Chief Operating Officer | 40 | 31/03/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Saad
BRD | Director/Board Member | 54 | 30/11/14 |
Susan Mahony
BRD | Director/Board Member | 60 | 10/10/23 |
Roger Jeffs
BRD | Director/Board Member | 62 | 30/11/14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.26% | 0 M€ | 0.00% | - | |
0.14% | 237 M€ | +2.89% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 71.71 | +0.27% | 272,333 |
25/04/24 | 71.52 | +0.49% | 412,254 |
24/04/24 | 71.17 | -2.61% | 583,799 |
23/04/24 | 73.08 | +2.78% | 703,139 |
22/04/24 | 71.1 | +4.71% | 498,859 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.90% | 3.41B | |
-4.26% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- AXSM Stock